An experimental treatment developed at Israel's Hadassah-University Medical Center has a 90% success rate at bringing patients with multiple myeloma into remission.
“Until now, this treatment has been available only in China and the US for nearly $400,000 per patient treatment, and it is very limited in its availability.”
“Until now, this treatment has been available only in China and the US for nearly $400,000 per patient treatment, and it is very limited in its availability.”